Table 3.
Impact of past SARS-CoV-2 infection on candidate markers of PACVS.
| PACVS ± COVID 1 | PACVS w/o COVID vs. post-vacc. CTR 2 | |||
|---|---|---|---|---|
| Median Effect Size 3 (%) | Significance (p) 4 | Median Effect Size 3 (%) | Significance (p) 4 | |
| AT1R | +12.8 | 0.01 | +43 | <0.0001 |
| ETAR | +7.9 | 0.11 | ||
| β2-adr-R | +7.2 | 0.07 | ||
| M3R | +20.3 | 0.05 | +44.4 | <0.0001 |
| IL-1-Rb | +6.3 | 0.08 | ||
| α2b-adr-R | +4.8 | 0.50 | ||
| M2R | +9.5 | 0.06 | ||
| MASR | +4.1 | 0.40 | ||
| IL-6 | −1.3 | 0.33 | ||
1 PanIg reactivity against SARS-CoV-2 nucleocapsid protein (N = 115 neg, N = 76 pos), 2 Six months after the second vaccination, SARS-CoV-2 nucleocapsid protein reactivity excluded (N = 89). 3 Differences between medians of groups, 4 p-values of differences between groups (U-test), significant differences are in bold.